Drug Trial Radar · NCT06556186
Surgical and Pharmacological Efficacy of Knosp Grade 0-2 Prolactinoma
Last checked: Nov 20, 2026Latest source record: Aug 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Oct 1, 2024
Primary completion
Mar 31, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Peking Union Medical College Hospital; West China Hospital; First Affiliated Hospital of Wenzhou Medical University; Ningbo Medical Center Lihuili Hospital
- First posted
- Aug 15, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators carried out a multi-center comparative study, involving hospitals including the Second Affiliated Hospital of Zhejiang University School of Medicine, Peking Union Medical College Hospital, West China Hospital, Wenzhou First Hospital, and Li Huili Hospital. This study aimed to compare the efficacy of medication and surgery for specific subtypes of microadenomas and clearly defined macroadenomas (Knosp grades 0-2), in order to determine which is more effective and which has fewer benefits, thereby enhancing the evidence base.
Conditions
- Pituitary Tumor
Interventions
Transnasal transsphenoidal pituitary lesion resection under neuroendoscopyProcedure
Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy
Bromocriptin 2.5mg, 2-3 times a dayDrug
Bromocriptin 2.5mg, 2-3 times a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- pituitary hormone levelsTime frame: At 1, 3, 6, 9 and 12 months postoperatively
- pituitary MRITime frame: At 1,6 and 12 months postoperatively
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.